MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-17-2026
Midatech Pharma plc Cash and Cash Equivalents 2011-2026 | MTP
Annual Cash and Cash Equivalents Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.67 M | 5.97 M | 2.84 M | 10.1 M | 7.55 M | 10.9 M | 2.34 M | 13.2 M | 17.6 M | 16.2 M | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.6 M | 1.67 M | 8.83 M |
Quarterly Cash and Cash Equivalents Midatech Pharma plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.1 M | - | - | - | 7.55 M | - | - | - | 10.9 M | - | - | - | 2.34 M | - | - | - | 13.2 M | - | - | - | 17.6 M | - | - | - | 16.2 M | - | - | - | 30.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.3 M | 2.34 M | 13.5 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
2.38 B | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
75.2 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 117.62 | 1.41 % | $ 27.2 B | Germany |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 11.66 | -8.95 % | $ 768 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
29.9 M | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
BioLineRx Ltd.
BLRX
|
10.4 M | $ 3.12 | 0.59 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 4.13 | -6.56 % | $ 116 M | France |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 233.49 | -0.81 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.71 | -0.46 % | $ 1.57 B |  Britain |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 2.04 | -2.39 % | $ 183 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
103 M | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
111 M | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Celldex Therapeutics
CLDX
|
28.4 M | $ 26.72 | 3.09 % | $ 1.72 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 94.24 | 1.38 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |